

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Buparvaquone Formulation
1.2	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Walton Manor, Walton MK7 7AJ Milton Keynes - United Kingdom
	Telephone	:	+1-908-740-4000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Skin irritation, Category 2 Eye irritation, Category 2 Reproductive toxicity, Category 1B	H315: Causes skin irritation. H319: Causes serious eye irritation. H360D: May damage the unborn child.
Specific target organ toxicity - single ex-	H335: May cause respiratory irritation.
posure, Category 3	nooo. May badde roopilatory initation.
Short-term (acute) aquatic hazard, Cate-	H400: Very toxic to aquatic life.
gory 1	
Long-term (chronic) aquatic hazard, Cat-	H410: Very toxic to aquatic life with long lasting
egory 1	effects.



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms :		! ***
Signal word :	Danger	• •
Hazard statements :	H315 H319 H335 H360D H410	Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. Very toxic to aquatic life with long lasting effects.
Precautionary statements :	Preventio P201 P264 P273 P280	n: Obtain special instructions before use. Wash skin thoroughly after handling. Avoid release to the environment. Wear protective gloves/ protective clothing/ eye protection/ face protection.
	Response P308 + P3 P391	

Hazardous components which must be listed on the label:

N-Methyl-2-pyrrolidone

Restricted to professional users.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
N-Methyl-2-pyrrolidone	872-50-4	Skin Irrit. 2; H315	>= 50 - < 70
	212-828-1	Eye Irrit. 2; H319	
	606-021-00-7	Repr. 1B; H360D	



According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Buparvaquone Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
6.0		9373397-00009	Date of first issue: 27.08.2021
Bupar	vaquone	88426-33-9	STOT SE 3; H335specific concentration limitSTOT SE 3; H335>= 10 %Eye Irrit. 2; H319Aquatic Acute 1;H400Aquatic Chronic 1;H410M-Factor (Acuteaquatic toxicity): 10M-Factor (Chronicaquatic toxicity): 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

4.2 Most important symptoms and effects, both acute and delayed

		···· ·
Risks	:	Causes skin irritation.
		Causes serious eye irritation.
		May cause respiratory irritation.
		May damage the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx)
5.3 Advice for firefighters Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing meth- ods	 Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
-------------------------------------	---

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures						
Personal precautions :		Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).				
6.2 Environmental precautions						
Environmental precautions	:	Avoid release to the environment.				



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 9373397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021			
		Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment barriers). Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Enviro ment Agency (emergency telephone number 0800 80706				
6.3 Method	Is and material for co	ntainment and cleani	ing up			
Methods for cleaning up		For large spills, p ment to keep ma be pumped, store Clean up remain bent. Local or national posal of this mate employed in the mine which regul Sections 13 and	rt absorbent material. provide dyking or other appropriate contain- terial from spreading. If dyked material can e recovered material in appropriate container. ing materials from spill with suitable absor- regulations may apply to releases and dis- erial, as well as those materials and items cleanup of releases. You will need to deter- lations are applicable. 15 of this SDS provide information regarding ational requirements.			

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Advice on safe handlingventilation.Advice on safe handling: Do not get on skin or clothing. Avoid breathing mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and s practice, based on the results of the workplace exposure sessment Keep container tightly closed. Already sensitised individuals, and those susceptible			
Advice on safe handlingventilation.Advice on safe handling: Do not get on skin or clothing. Avoid breathing mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and s practice, based on the results of the workplace exposure sessment Keep container tightly closed. Already sensitised individuals, and those susceptible	echnical measures	:	
Avoid breathing mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and s practice, based on the results of the workplace exposure sessment Keep container tightly closed. Already sensitised individuals, and those susceptible	ocal/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
should consult their physician regarding working with res tory irritants or sensitisers.	dvice on safe handling	:	Avoid breathing mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira- tory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the
flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash con nated clothing before re-use.	łygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024		DS Number: 373397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
			appropriate dego	rols, proper personal protective equipment, winng and decontamination procedures, e monitoring, medical surveillance and the ative controls.		
7.2 Condit	ions for safe storage,	, inc	luding any incom	patibilities		
Requirements for storage areas and containers		:	Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.			
Advice	e on common storage	ge : Do not store with the following produ Strong oxidizing agents Self-reactive substances and mixtur Organic peroxides Explosives Gases		agents stances and mixtures		
•	c end use(s) ic use(s)	:	No data available	9		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
N-Methyl-2-	872-50-4	TWA	10 ppm	GB EH40		
pyrrolidone			40 mg/m3			
	Further inforn	nation: Can be absor	bed through the skin. The as	signed sub-		
	stances are t	nose for which there	are concerns that dermal ab	sorption will		
	lead to syster	nic toxicity.		•		
		STEL	20 ppm	GB EH40		
			80 mg/m3			
	Further inforn	nation: Can be absor	bed through the skin. The as	signed sub-		
			are concerns that dermal ab	•		
		lead to systemic toxicity.				
		TWA 10 ppm 200				
			40 mg/m3			
		Further information: Identifies the possibility of significant uptake through the skin, Indicative				
	· · ·	STEL 20 ppm 20				
			80 mg/m3			
	Further inform	nation: Identifies the	possibility of significant uptal	ke through the		
	skin, Indicativ			Ũ		
		TWA	10 ppm	2004/37/EC		
			40 mg/m3			
	Further inform	nation: Skin, Carcino		1		
		STEL	20 ppm	2004/37/EC		
			80 mg/m3			

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 9373397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	

	Further information: Skin, Carcinogens or mutagens				
Buparvaquone	88426-33-9	TWA	40 µg/m3 (OEB 3)	Internal	
		Wipe limit	400 μg/100 cm ²	Internal	

Derived No Effect Level (DNEL)

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
N-Methyl-2- pyrrolidone	Workers	Inhalation	Long-term systemic effects	14.4 mg/m3
	Workers	Inhalation	Long-term local ef- fects	40 mg/m3
	Workers	Skin contact	Long-term systemic effects	4.8 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	3.6 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	4.5 mg/m3
	Consumers	Skin contact	Long-term systemic effects	2.4 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.85 mg/kg bw/day

Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value
N-Methyl-2-pyrrolidone	Fresh water	0.25 mg/l
	Freshwater - intermittent	5 mg/l
	Marine water	0.025 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1.09 mg/kg dry weight (d.w.)
	Marine sediment	1.09 mg/kg dry weight (d.w.)
	Soil	0.07 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

:

Eye/face protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 9373397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Hand	I protection	potential for d aerosols.	lirect contact to the face with dusts, mists, or
Ма	aterial	: Chemical-resi	stant gloves
	emarks and body protection	 Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upor being performed (e.g., sleevelets, apron, gauntlets, di suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove po 	
Resp	iratory protection	sure assessm ommended gu	cal exhaust ventilation is not available or expo- ent demonstrates exposures outside the rec- lidelines, use respiratory protection. ould conform to BS EN 14387
Fil	ter type		ticulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	liquid clear, red No data available No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	1 (20 °C)
Density	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 9373397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature Decomposition temperature		 No data availa Not applicable No data availa No data availa 	ble
Visco Vis	sity scosity, kinematic	: No data availa	ble
Explosive properties		: Not explosive	
Oxidizing properties		: The substance	e or mixture is not classified as oxidizing.
9.2 Other information Flammability (liquids) Particle size		: No data availa : Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

ersion .0	Revision Date: 28.09.2024		9S Number: 73397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
			Eye contact	
Acute	toxicity			
Not cla	assified based on availa	ble	information.	
<u>Comp</u>	onents:			
N-Met	hyl-2-pyrrolidone:			
Acute	oral toxicity	:	LD50 (Rat): 4,1	50 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 5.1 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403	
Acute	dermal toxicity	:	LD50 (Rat): > 5	i,000 mg/kg
Bupar	vaquone:			
Acute	oral toxicity	:	LD50 (Rat): > 8	,000 mg/kg
			LD50 (Mouse): Remarks: No m	> 50 mg/kg nortality observed at this dose.
	toxicity (other routes of istration)	:	LD50: 2.5 mg/k Application Rou	
	corrosion/irritation			
<u>Comp</u>	onents:			
N-Met	hyl-2-pyrrolidone:			
Result	• • • •	:	Skin irritation	
Bupar	vaquone:			
Specie Result	es	:	Mouse Mild skin irritatio	on
	us eye damage/eye irri es serious eye irritation.	tati	on	
<u>Comp</u>	onents:			
N-Met	hyl-2-pyrrolidone:			
Specie Result	es	:	Rabbit Irritation to eyes	s, reversing within 21 days
Bupar Result	vaquone:	:	Mild eye irritatio	on

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Test Type	: Local lymph node assay (LLNA)
Test Type Exposure routes Species Method Result Remarks	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative	
		Test Type: DNA damage and repair, unscheduled DNA syn- thesis in mammalian cells (in vitro) Result: negative	
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 474 Result: negative	
		Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Hamster Application Route: Ingestion Method: OECD Test Guideline 475 Result: negative	

Carcinogenicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	SDS Number: 9373397-00009		Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
Comp	onents:				
N-Met	hyl-2-pyrrolidone:				
	ation Route sure time	:	Rat Ingestion 2 Years negative		
Applic Expos	Species:Application Route:Exposure time:Result:		Rat inhalation (vapour 2 Years negative)	
-	ductive toxicity amage the unborn child	d.			
Comp	onents:				
	hyl-2-pyrrolidone:				
Effect	s on fertility		Test Type: Two-g Species: Rat Application Route Method: OECD Te Result: negative		
Effect: ment	s on foetal develop-		Test Type: Embry Species: Rat Application Route Method: OECD Te Result: positive		
			Species: Rat	y/early embryonic development : inhalation (vapour)	
			Test Type: Embry Species: Rabbit Application Route Result: positive	o-foetal development : Ingestion	
Repro sessm	ductive toxicity - As- nent		Clear evidence of animal experimen	adverse effects on development, based on ts.	
May c	STOT - single exposure May cause respiratory irritation.				
	oonents:				
N-Met Asses	hyl-2-pyrrolidone: sment	:	May cause respira	atory irritation.	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

N-Methyl-2-pyrrolidone:

Species NOAEL LOAEL Application Route Exposure time Method	 Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Guideline 408
Species NOAEL LOAEL Application Route Exposure time Method	 Rat 0.5 mg/l 1 mg/l inhalation (dust/mist/fume) 96 Days OECD Test Guideline 413
Species NOAEL LOAEL Application Route Exposure time	 Rabbit 826 mg/kg 1,653 mg/kg Skin contact 20 Days
Buparvaquone: Species NOAEL Application Route Exposure time Remarks NOAEL Application Route Exposure time Remarks	 Cat 10 mg/kg Intramuscular 5 d No significant adverse effects were reported 5 mg/kg Intravenous 4 d No significant adverse effects were reported
Species NOAEL Application Route Exposure time Remarks	 Mouse 50 mg/kg Oral 6 d No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024	-	9S Number: 73397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
Expe	rience with human exp	osu	ire	
Com	ponents:			
	thyl-2-pyrrolidone: contact	:	Symptoms: Skin i	rritation
SECTION	12: Ecological infor	ma	tion	
12.1 Toxic	city			
Com	ponents:			
	t hyl-2-pyrrolidone: ity to fish	:	LC50 (Oncorhync Exposure time: 96	hus mykiss (rainbow trout)): > 500 mg/l 5 h
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 24 Method: DIN 384	
Toxic plants	ity to algae/aquatic	:	ErC50 (Desmode Exposure time: 72	smus subspicatus (green algae)): 600.5 mg/l ? h
			EC10 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 92.6 mg/l ? h
Toxic	ity to microorganisms	:	EC50 : > 600 mg/ Exposure time: 30 Method: ISO 8192) min
	ity to daphnia and other tic invertebrates (Chron- icity)	:	NOEC: 12.5 mg/l Exposure time: 21 Species: Daphnia Method: OECD To	magna (Water flea)
Bupa	irvaquone:			
	ity to fish	:	LC50 (Brachydan Exposure time: 96 Method: OECD To	
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
M-Fa icity)	ctor (Acute aquatic tox-	:	10	
M-Fa toxicit	ctor (Chronic aquatic ty)	:	10	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

12.2 Persistence and degradability

Components:

N-Methyl-2-pyrrolidone:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 73 %
		Exposure time: 28 d
		Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

N-Methyl-2-pyrrolidone:

Partition coefficient: n-	:	log Pow: -0.46
octanol/water		Method: OECD Test Guideline 107

Buparvaquone:

Partition coefficient: n-	:	log Pow: 6.5
octanol/water		-

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment	: This substance/mixture contains no components considered
Assessment	
	to be either persistent, bioaccumulative and toxic (PBT), or
	very persistent and very bioaccumulative (vPvB) at levels of
	0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-	:	This substance/mixture does not contain components consid-
tial		ered to have endocrine disrupting properties for environment
		according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods		
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. 	
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. 	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Version 6.0	Revision Date: 28.09.2024		DS Number: 973397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
			If not otherwise s	pecified: Dispose of as unused product.
SECTION	I 14: Transport infor	mat	tion	
14.1 UN n	umber			
ADN		:	UN 3082	
ADR		:	UN 3082	
RID		:	UN 3082	
IMDG	i	:	UN 3082	
ΙΑΤΑ		:	UN 3082	
14.2 UN p	roper shipping name			
ADN		:	ENVIRONMENT N.O.S. (Buparvaquone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ADR		:	ENVIRONMENT N.O.S. (Buparvaquone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
RID		:	ENVIRONMENT N.O.S. (Buparvaquone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
IMDG	i	:	ENVIRONMENT/ N.O.S. (Buparvaquone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ΙΑΤΑ		:	Environmentally I (Buparvaquone)	nazardous substance, liquid, n.o.s.
14.3 Trans	sport hazard class(es)			
			Class	Subsidiary risks
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG	i	:	9	
ΙΑΤΑ		:	9	
14.4 Pack	ing group			
Class Hazaı Label: ADR Packi	ng group ification Code rd Identification Number s ng group ification Code		III M6 90 9 1II M6	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Buparvaquone Formulation

Vers 6.0	sion	Revision Date: 28.09.2024		9S Number: 73397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
	Labels	Identification Number restriction code	: : :	90 9 (-)	
		g group cation Code Identification Number	: : :	III M6 90 9	
	IMDG Packing Labels EmS Co		:	III 9 F-A, S-F	
	aircraft)	g instruction (cargo g instruction (LQ)	:	964 Y964 III Miscellaneous	
	Packing ger airc	g instruction (LQ)	:	964 Y964 III Miscellaneous	
14.5	5 Enviro	nmental hazards			
	ADN Environ	mentally hazardous	:	yes	
	ADR Environ	mentally hazardous	:	yes	
	RID Environ	mentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) mentally hazardous	:	yes	
	IATA (C Environ	Cargo) mentally hazardous	:	yes	
14.6	Specia	I precautions for use	r		

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (A	nnex 17)	:	Conditions of restri lowing entries shou Number on list 3	
UK REACH List of restrictions (A	nnex 17)		Number on list 30: pyrrolidone	N-Methyl-2-
			Number on list 71: pyrrolidone	N-Methyl-2-
UK REACH List of restrictions (A	nnex 17)		Number on list 72: pyrrolidone	N-Methyl-2-
			Substance(s) or mi here according to t in the regulation, ir use/purpose or the restriction. Please tions in correspond determine whether cable to the placing not.	heir appearance respective of their conditions of the refer to the condi- ling Regulation to an entry is appli-
UK REACH Candidate list of sub- concern (SVHC) for Authorisation		:	N-Methyl-2-pyrrolic	done
The Persistent Organic Pollutants Regulation (EU) 2019/1021 as ar ain)		:	Not applicable	
Regulation (EC) on substances the layer	nat deplete the ozone	:	Not applicable	
UK REACH List of substances su (Annex XIV)	bject to authorisation	:	Not applicable	
GB Export and import of hazardo Informed Consent (PIC) Regulation		:	Not applicable	
Control of Major Accident Hazard		MA		
E1	ENVIRONMENTAL HAZARDS		Quantity 1 100 t	Quantity 2 200 t

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.



Buparvaquone Formulation

Vers 6.0	ion	Revision Date: 28.09.2024		DS Number: 73397-00009	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		omponents of this p	roduc	•	the following inventories:
	AICS		:	not determined	
	DSL		:	not determined	
	IECSC		:	not determined	
15.2	Chemi	cal safety assessm	ent		
A Ch	nemical	Safety Assessment	has n	ot been carried out	
SEC		16: Other informa	tion		
	Other i	nformation	:		ges have been made to the previous version the body of this document by two vertical
	Full tex	xt of H-Statements			
	H315		:	Causes skin irrita	
	H319		:	Causes serious e	
	H335 H360D		:	May cause respire	
	H400		:	May damage the Very toxic to aqua	
	H410		÷		atic life with long lasting effects.
		xt of other abbrevia	tions		
	Aquatio	c Acute	:	Short-term (acute) aquatic hazard
		c Chronic	:		ic) aquatic hazard
	Eye Irri	t.	:	Eye irritation	
	Repr.		:	Reproductive toxi	city
	Skin Irr		:	Skin irritation	
	STOT S		:		gan toxicity - single exposure
	2004/3	//EC	-	from the risks rela	2004/37/EC on the protection of workers ated to exposure to carcinogens or mutagens
	2000/4	64/EU		at work	SION DIDECTIVE 2000/161/ELL establishing
	2009/1	61/EU	:	a third list of indic implementation o	SION DIRECTIVE 2009/161/EU establishing ative occupational exposure limit values in f Council Directive 98/24/EC and amending
		10		Commission Dire	
	GB EH		:		Workplace Exposure Limits
		7/EC / STEL 7/EC / TWA		Short term expos	
		61/EU / TWA	:	Limit Value - eigh	
		61/EU / STEL	:	Short term expos	
		40 / TWA	:		ure limit (8-hour TWA reference period)
		40 / STEL	:		ure limit (15-minute reference period)
				•	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:
Skin Irrit. 2	H315	Calculation method
Eye Irrit. 2	H319	Calculation method
Repr. 1B	H360D	Calculation method
STOT SE 3	H335	Calculation method
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



Buparvaquone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.0	28.09.2024	9373397-00009	Date of first issue: 27.08.2021

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN